Literature DB >> 29450723

Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma.

David Taïeb1, Karel Pacak2.   

Abstract

Pheochromocytomas and their extra-adrenal counterpart paragangliomas (PGLs; together called PPGLs), belong to the family of neural crest-derived tumors. Given the overexpression of a wide variety of specific targets in PPGLs, it seems that these tumors are optimally suited to be imaged by specific radiopharmaceuticals. Thus, theranostics approaches with somatostatin agonists and antagonists are rapidly evolving in the setting of these tumors and may be considered as the next step in the therapeutic arsenal of metastatic PPGLs.

Entities:  

Keywords:  6-(18F)fluoro-L-3,4-dihydroxyphenylalanine; DOTA-analogues; Gallium-68; Neuroendocrine; Paragangliomas; Positron emission tomography; Somatostatin

Mesh：

Substances：

Year:  2018        PMID： 29450723      PMCID： PMC7442158          DOI： 10.1007/s00441-018-2791-4

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN： 0302-766X            Impact factor:   5.249


  30 in total

1.  False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.

Authors:  Jay S Fonte; Jeremyjones F Robles; Clara C Chen; James Reynolds; Millie Whatley; Alexander Ling; Leilani B Mercado-Asis; Karen T Adams; Victoria Martucci; Tito Fojo; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2012-02-13       Impact factor: 5.678

2.  Malignant pheochromocytoma imaging with [124I]mIBG PET/MR.

Authors:  Verena Hartung-Knemeyer; Sandra Rosenbaum-Krumme; Christian Buchbender; Thorsten Pöppel; Wolfgang Brandau; Walter Jentzen; Gerald Antoch; Michael Forsting; Andreas Bockisch; Hilmar Kühl
Journal:  J Clin Endocrinol Metab       Date:  2012-09-07       Impact factor: 5.958

3.  Pheochromocytomas: detection with 18F DOPA whole body PET--initial results..

Authors:  Stefan Hoegerle; Egbert Nitzsche; Carsten Altehoefer; Nadir Ghanem; Tanja Manz; Ingo Brink; Martin Reincke; Ernst Moser; Hartmut P H Neumann
Journal:  Radiology       Date:  2002-02       Impact factor: 11.105

4.  The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome.

Authors:  Priya Kaji; Jorge A Carrasquillo; W Marston Linehan; Clara C Chen; Graeme Eisenhofer; Peter A Pinto; Edwin W Lai; Karel Pacak
Journal:  Eur J Endocrinol       Date:  2007-04       Impact factor: 6.664

5.  Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma.

Authors:  Grace Kong; Simona Grozinsky-Glasberg; Michael S Hofman; Jason Callahan; Amichay Meirovitz; Ofra Maimon; David A Pattison; David J Gross; Rodney J Hicks
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

Review 6.  Pheochromocytoma: an imaging chameleon.

Authors:  Michael A Blake; Mannudeep K Kalra; Michael M Maher; Dushyant V Sahani; Ann T Sweeney; Peter R Mueller; Peter F Hahn; Giles W Boland
Journal:  Radiographics       Date:  2004-10       Impact factor: 5.333

7.  Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation.

Authors:  Michael S Hofman; W F Eddie Lau; Rodney J Hicks
Journal:  Radiographics       Date:  2015 Mar-Apr       Impact factor: 5.333

8.  6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.

Authors:  Helle-Brit Fiebrich; Adrienne H Brouwers; Michiel N Kerstens; Milan E J Pijl; Ido P Kema; Johan R de Jong; Pieter L Jager; Philip H Elsinga; Rudi A J O Dierckx; Jacqueline E van der Wal; Wim J Sluiter; Elisabeth G E de Vries; Thera P Links
Journal:  J Clin Endocrinol Metab       Date:  2009-07-21       Impact factor: 5.958

9.  Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.

Authors:  Sara Gonias; Robert Goldsby; Katherine K Matthay; Randall Hawkins; David Price; John Huberty; Lloyd Damon; Charles Linker; Aimee Sznewajs; Steve Shiboski; Paul Fitzgerald
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

10.  Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma.

Authors:  Ioannis Ilias; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Alexander Ling; Ivica Lazúrová; Karen T Adams; Shiromi Perera; Karel Pacak
Journal:  J Nucl Med       Date:  2008-09-15       Impact factor: 10.057
View more
  10 in total

Review 1.  From Diagnosis to Therapy-PET Imaging for Pheochromocytomas and Paragangliomas.

Authors:  Hiren V Patel; Arnav Srivastava; Murray D Becker; Toni Beninato; Amanda M Laird; Eric A Singer
Journal:  Curr Urol Rep       Date:  2021-01-06       Impact factor: 3.092

Review 2.  Novel PET tracers: added value for endocrine disorders.

Authors:  Sébastien Bergeret; Judith Charbit; Catherine Ansquer; Géraldine Bera; Philippe Chanson; Charlotte Lussey-Lepoutre
Journal:  Endocrine       Date:  2019-03-14       Impact factor: 3.633

Review 3.  Neuroendocrine Neoplasms of the Female Genitourinary Tract: A Comprehensive Overview.

Authors:  Mayur Virarkar; Sai Swarupa Vulasala; Dheeraj Gopireddy; Ajaykumar C Morani; Taher Daoud; Rebecca Waters; Priya Bhosale
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

Review 4.  Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management.

Authors:  Amrish Jain; Rossana Baracco; Gaurav Kapur
Journal:  Pediatr Nephrol       Date:  2019-01-02       Impact factor: 3.714

5.  Genetic stratification of inherited and sporadic phaeochromocytoma and paraganglioma: implications for precision medicine.

Authors:  Ruth Casey; Hartmut P H Neumann; Eamonn R Maher
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

Review 6.  The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?

Authors:  Rudolf A Werner; Alexander Weich; Malte Kircher; Lilja B Solnes; Mehrbod S Javadi; Takahiro Higuchi; Andreas K Buck; Martin G Pomper; Steven P Rowe; Constantin Lapa
Journal:  Theranostics       Date:  2018-11-29       Impact factor: 11.556

Review 7.  Haemorrhagic retroperitoneal paraganglioma initially manifesting as acute abdomen: a rare case report and literature review.

Authors:  Yanliang Yang; Guangzhi Wang; Haofeng Lu; Yaqing Liu; Shili Ning; Fuwen Luo
Journal:  BMC Surg       Date:  2020-11-30       Impact factor: 2.102

Review 8.  Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World.

Authors:  Mayank Patel; Isabel Tena; Abhishek Jha; David Taieb; Karel Pacak
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-29       Impact factor: 5.555

Review 9.  Progress in the diagnosis and treatment of paraganglioma.

Authors:  Ben Wang; Jian Qiu
Journal:  Transl Cancer Res       Date:  2019-11       Impact factor: 1.241

Review 10.  Frequently asked questions and answers (if any) in patients with adrenal incidentaloma.

Authors:  F Ceccato; M Barbot; C Scaroni; M Boscaro
Journal:  J Endocrinol Invest       Date:  2021-06-23       Impact factor: 4.256
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.